Slides
Page 1
Jan 2024 Strategy Meeting February 2026 H1 FY26 Results & Company Presentation Blair Vega Norfolk Founder & Managing Director For personal use only
Page 2
Biome Australia #1 fastest growing probiotic brand, ACTIVATED PROBIOTICS, in Australian pharmacy 100% of product range in growth. Full-margin growth without promotional discounting. Proprietary IP pipeline with first human clinical trial underway BMB18TM strain, 240-participant RCT with La Trobe University Record revenue, record profit, 40% growth $12.40m H1 revenue | $6.45m Q2 revenue | $1.18m net profit | 8 consecutive EBITDA quarters For personal use only
Page 3
H1 FY26 Financial Scorecard Record results across all key metrics Revenue $12.40m +40% vs PCP Adj. EBITDA $1.47m 8th consecutive quarter Net Profit $1.18m +172% vs PCP Gross Margin 61.1% Achieved (1H25: 61.0%) Op. Cash Flow $2.09m $3.21m turnaround EPS 0.53c +165% vs PCP For personal use only
Page 4
Operating Leverage Now Visible Earnings growth significantly outpacing revenue growth Revenue & Cash Receipts ($m) EBITDA* (Adj) & Net Profit ($m) Revenue +40% +100% Net Profit +172% Cash Receipts +62% EBITDA For personal use only
Page 5
Market Opportunity Large, growing global market with significant runway in Australia and internationally Global Probiotics Market ~US$75B+ estimated 2025, growing 7-8% CAGR Dietary supplements the fastest growing segment at ~12% CAGR Australian Probiotics Market ~A$600M estimated domestic market Biome is #1 growth brand with significant headroom to scale How Biome Has De-Risked the Opportunity #1 growth brand Category leadership established across community pharmacy, TWC, Priceline, and wholesale Revenue at scale Annualised run rate of ~$25.8m with 40% growth, proving product-market fit and repeat demand 5 markets live Practitioner-only model validated in Australia and now replicating in Canada, Ireland, UK, and New Zealand Distribution built 7,000+ points from 100 in FY19. TAM ~12,000. Current penetration ~58% with significant upside For personal use only
Page 6
About Biome Australia Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven, condition-specific probiotic products fueled by novel clinical research programs to cement and extend the evidence base of its probiotic products. Activated Probiotics, Biome’s flagship range of novel live-biotherapeutics (probiotics), was created in partnership with world leading organisations in microbiome research and utilises innovative delivery technologies that improves their stability and efficacy. Biome has a B Corporation certification, a designation that a business is meeting high standards of verified performance, accountability and transparency. For personal use only
Page 7
A range of condition specific probiotics Activated Probiotics has selected specific strains for various health conditions and aspects of health to create a range of precision probiotics 7 For personal use only
Page 8
Selective formulations with clinically validated applications 8 For personal use only
Page 9
Clinically Proven Product Range The majority of products are supported by published clinical trials on the finished product Mood, Sleep & Depression Biome Lift™ 3 RCTs on finished product Clinically proven for mood, sleep quality, and subthreshold depression Bone Health Biome Osteo™ Published in The Lancet 78% reduction in bone loss vs placebo in landmark clinical trial Immune & Respiratory Biome Breathe™ RCT on finished product 64% reduction in asthma events vs placebo Cholesterol Biome Cholesterol™ 5 RCTs on finished product Significant LDL reduction. Proven safe alongside statins Skin: Eczema Biome Eczema™ RCT on finished product 52% reduction in eczema SCORAD score vs placebo Skin: Acne Biome Acne™ RCT on finished product 39% reduction in acne lesions vs placebo Iron Absorption Biome Iron+™ Clinical trial published More than 50% increase in iron absorption with a fruit juice Children's Health Biome Daily Kids™ Federation Uni clinical trial Paediatric-specific formulation with clinically documented strains This depth of clinical evidence across a full product range is unique in the global probiotics market and underpins the practitioner recommendation model For personal use only
Page 10
Clinical Evidence as Competitive Moat The evidence base is what makes the practitioner model work. Without it, there is no recommendation. Clinically Documented Strains Every product formulated with strains supported by published clinical evidence. Not marketing claims. Practitioners require this standard before recommending. Condition-Specific Formulations 18 products across two brands, each targeting a defined health condition. Enables practitioners to prescribe by indication, exactly as they would a pharmaceutical product. Complementary to Medical Treatment Positioned alongside, not instead of, medical interventions. Practitioners recommend with confidence because the products complement existing care plans and are free from any known drug interactions. Why This Is Difficult to Replicate Clinical evidence requires years of investment Practitioner trust built through education Recommendation drives pharmacy ranging Scan data proves performance, deepens ranging New entrants cannot shortcut this process For personal use only
Page 11
Adjunct Medication Opportunities ATC medication category Medication volume July 2020–June 2021 Activated Probiotics product with adjunct opportunities General Anti-infectives 10M Prescriptions per year Biome Advanced™ Probiotic To help restore the balance of beneficial gut bacteria after antibiotic use Nervous System 48M Prescriptions per year Biome Lift™ Probiotic To support healthy mood balance and enhance sleep quality Respiratory System 12M Prescriptions per year Biome Breathe™ Probiotic To help stimulate a healthy immune system response in children Dermatological 3M Prescriptions per year Biome Eczema™ Probiotic To help reduce the symptoms of mild eczema Musculo-skeletal System 7M Prescriptions per year Biome Osteo™ Probiotic To help promote bone healthy in adults Cardiovascular System 29M Prescriptions per year Biome Cholesterol™ Probiotic To help support healthy cholesterol levels in healthy adults Source: http://medicarestatistics.humanservices.gov.au/statistics/pbs_group.jsp Condition-specific range enables multiple products per patient, positioned alongside medical treatment Activated Probiotics are recommended by practitioners as complementary to existing medical treatment, not as alternatives. This positions Biome alongside pharmaceutical and medical interventions rather than competing with mass-market supplements. The clinical evidence base gives practitioners the confidence to actively recommend, creating a fundamentally different demand model to traditional VMS brands. For personal use only
Page 12
Market Position The fastest growing brand in the biggest category in pharmacy #1 Community Pharmacy (ex CW) Probiotic brand by revenue Fastest growing in category #2 Terry White Chemmart Total vitamins Fastest growing in category 48%+ Priceline Pharmacy MAT scan sales growth Significant headroom for further growth #1 Wholesale (Symbion/API) Growth brand VMS category 100% of range in growth For personal use only
Page 13
The Pull Model Full-margin growth without promotional discounting Traditional VMS Model Push Growth driven by promotional cycles and discounting Margin erosion as brands scale Price-sensitive, substitutable demand Retailer controls the relationship High cost of customer acquisition Biome Model Pull Growth driven by practitioner recommendation 61% gross margin achieved and maintained at scale Evidence-based demand, high brand loyalty ~2.5 units per transaction, 6 visits per year (TWCM data) Consumer seeks the product by name For personal use only
Page 14
The Practitioner Flywheel Our competitive moat: practitioner endorsement drives category leadership 1 Practitioner Education Health-qualified consultants deliver clinical training 2 Practitioner Recommendation Trusted endorsement drives patient purchase 3 Pharmacy Purchase ~2.5 units per transaction, 6 visits/year (TWCM data) 4 Scan Data Validates Category growth drives deeper ranging 5 Category Leadership #1 growth brand reinforces practitioner confidence Repeat purchase behaviour compounds growth across all channels For personal use only
Page 15
Training and Education Driven Sales Model — Practitioner Only Unique Education and Service Model Drives Sales in Australia, UK and NZ Education and Service Support The Biome sales team is a mix of health qualified practitioner education consultants and territory managers Practitioner education consultants undertake high level product detailing and training in community pharmacy and with independent health practitioners High quality training and education develops stronger trust and relationships with health practitioners Biomes support leads to active recommendations of Biome Australia products Digital educational content and assets effectively support the national sales team in servicing practitioner markets Health Clinics are provided to key accounts to gain trust and develop existing accounts For personal use only
Page 16
Rolling 12 Months and Quarterly Sales Revenue For personal use only
Page 17
● Biome has grown its Australian distribution from 100 distribution points in 2019 to 7000+ in FY26 — the total addressable distribution market for Biome in our local market is ~12,000. ● Existing distribution (7000+) is expected to be ~58% developed at the close of H1 FY26. This leaves significant potential for scale in both number of accounts and average account revenue through Vision 27 and beyond. ● FY26 estimated 7500 by end of FY26. Distribution growth and business development For personal use only
Page 18
Clinical & IP Pipeline Proprietary IP strategy building long-term competitive advantage Discovery Preclinical Ethics Approval Human Trial Results & Product Dev BMB18TM Lactobacillus plantarum BMB18TM Human Clinical Trial Trial Design: Randomised, double-blind, placebo-controlled | Participants: 240 | Partner: La Trobe University Commenced: February 2026 | Strain Bank: Registered with DSMZ (Germany) | IP Status: Proprietary to Biome Australia Existing Clinical Evidence Base (30+ RCT studies on Biome’s finished products) Including: Biome Lift (mood & sleep) Biome Osteo (bone health) Biome Daily Kids (paediatric) For personal use only
Page 19
BMB18™: Proprietary Strain Development Lactobacillus plantarum BMB18 | 100% owned by Biome Australia | DSMZ registered In Vitro Study Results Completed by European research partner Immune Modulation Strong ability to modulate immune responses and inflammation Oxidative Stress Reduction Demonstrated capacity to reduce oxidative stress markers Gut Barrier Integrity Maintained intestinal barrier integrity, reducing leaky gut Human Clinical Trial Commenced February 2026 Design: Randomised, double-blind, placebo-controlled Participants: 240 across two active dosage levels Partner: La Trobe University Duration: 12 months Cost: ~$140,000 (within existing R&D budget) Registry: ANZCTR (Australia New Zealand Clinical Trials) Target Conditions Digestive symptoms (bloating, discomfort) Sleep disturbances Mood disturbances Quality of life outcomes Development Pipeline Strain Identification Commercial Validation DSMZ Deposit In Vitro Characterisation Human Clinical Trial Product Development 100% Biome-owned IP Reduces COGS via proprietary strain Future licensing opportunity Long-term balance sheet asset For personal use only
Page 20
International Expansion Four markets now contributing to revenue Established Australia 7000+ distribution points TWC, Priceline, Symbion, API Mecca, Go Vita Growing Canada Fullscript (practitioner platform) Ecotrend (national wholesale) Territory managers in ON, BC & Q Launched Ireland & UK Uniphar (wholesale distribution) Pharmacy access established Launched July 2025 Launched New Zealand Propharma (EBOS Group) Green Cross Health Dual-channel model For personal use only
Page 21
H2 Outlook & Growth Catalysts Winter Immunity Campaign First major above-the-line national advertising campaign. Outdoor, digital, and co-branded activity with key retail partners. Timed to coincide with peak demand period. International Momentum Canada accelerating with Fullscript now live alongside Ecotrend. Ireland and New Zealand partnerships continuing to build. UK market under development. BMB18TM Clinical Trial 240-participant randomised controlled trial underway with La Trobe University. Results will support proprietary product development and strengthen IP portfolio. Category Expansion Active product pipeline under evaluation to extend the Activated Probiotics and Activated Therapeutics ranges into new therapeutic categories. For personal use only
Page 22
Investment Case Category Leader #1 fastest growing probiotic brand in Australia's biggest pharmacy category. 100% of range in growth. Premium Margin Model 61% gross margin achieved at scale without promotional discounting. Pull-based demand driven by practitioner endorsement sustains full-margin growth with long product lifecycles. Operating Leverage Proven Net profit up 172%. Operating cash flow turnaround of $3.28m. Eighth consecutive EBITDA positive quarter. Proprietary IP Pipeline BMB18TM strain in human clinical trial. DSMZ registered. Long-term balance sheet asset under development. International Optionality Four markets live. Practitioner-only model replicating across Canada, Ireland, and New Zealand. Fully Funded Growth No capital required. Borrowings halved. Cash generative. Annualised run rate of ~$25.8m ($6.45m Q2 exit run rate). For personal use only
Page 23
Shaping the Industry Biome plays an active role in advancing standards, regulation, and education across the complementary medicine industry Complementary Medicines Australia (CMA) Board Director CMA is the peak industry body representing the complementary medicines sector in Australia, advocating for regulatory frameworks, market access, and evidence-based standards across the industry. International Probiotics Association (IPA) Board Director The IPA is the global voice of the probiotics industry, representing companies across research, manufacturing, and distribution. Membership includes leading probiotic producers worldwide. What This Reflects Direct input into regulatory and policy decisions that shape the Australian and global probiotics landscape Industry recognition of Biome's scientific credibility and evidence-based approach to product development Relationships with the world's leading probiotic researchers, manufacturers, and distribution partners Visibility and influence that support commercial partnerships and international market access For personal use only
Page 24
Contact details Blair Norfolk, CEO Lauren Dwyer, CFO Email corporate@biomeaustralia.com Websites biomeaustralia.com activatedprobiotics.com.au For personal use only
Page 25
Disclaimer This presentation and the information contained within it (the “information”) has been prepared solely for the use and benefit of the person to whom it is provided (the “recipient”). It has been provided to the recipient on a strictly confidential basis solely for the purpose of assisting the recipient to determine whether it may be interested in participating in the investment opportunity described in this presentation (“Opportunity”) and if so, to participate in that process, and may only be used for that purpose. This presentation contains selected information only and does not purport to contain all of the information that may be relevant to the Opportunity. The information is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. This presentation has not been filed, registered or approved in any jurisdiction. The information is provided for general information purposes only, without taking into account any person’s objectives, financial situation or needs. It should not be relied on by the recipient in considering the merits of any particular transaction, including the Opportunity. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment of the contents of the Information. Past performance information included in this presentation is provided for illustrative purposes only, should not be relied upon and is not an indication of future performance. Biome Australia Limited (“Company”) and its related bodies corporate, directors, officers, partners, employees, advisers, consultants and agents make no representation nor give any warranty, express or implied, as to the accuracy, completeness, reliability, timeliness or suitability of the information or that the information may be used in any given way or to achieve any given result. This presentation contains forward-looking statements, which may be identified by words such as ‘may’ , ‘could’ , ‘believes’ , ‘estimates’ , ‘expects’ or ‘intends’ and other similar words that connote risks and uncertainties. Certain statements, beliefs, and opinions contained in this presentation, in particular those regarding the possible or assumed future financial or other performance, industry growth or other trend projections are predictions only, and not guarantees, and subject to inherent risks and uncertainties. Except to the extent required by law, none of the Company, its Related Persons or any other person gives any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur and investors are cautioned not to place undue reliance on such forward-looking statements. A summary of the key risks associated with the Company, its business and an investment in its shares is set out at the end of this presentation. All forward-looking statements are subject to risk factors, many of which are beyond the control of the Company and its Related Persons and, if they were to occur, could cause the Company’s actual financial results to differ materially from the results expressed or anticipated in the forward-looking statements. The information should be read in conjunction with the risk factors set out at the end of this presentation. The information is based on an assessment of the economic and operating conditions as at the date of this presentation, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Except to the extent required by law, the Company and its Related Parties will not be updating or revising the information. The recipient must, and agrees with the Company that it will, make its own independent assessment of the accuracy, completeness, reliability, timeliness and suitability of the information and its own determination of whether the information is appropriate to be used for any given purpose. The recipient will rely upon the information at its own risk. To the maximum extent permitted by law, the Company and its Related Persons exclude and disclaim all liability for any loss, damage, cost or expense suffered by the recipient or any other person arising from or in connection with use or reliance on (in any manner) the information or the recipient’s participation in the Opportunity, whether the loss, damage, cost or expense arise because of negligence, default, misrepresentation or some other cause, and whether or not foreseeable. To the maximum extent permitted by law, the recipient (on its own behalf and on behalf of each of its representatives) unconditionally and irrevocably releases the Company and its Related Persons from all claims and liability. The Company holds this release for itself and on trust for its Related Persons. The information contained in this presentation represents the Company’s strategy as determined by the board of directors as at the date of this presentation (25 February 2026), and the board reserves its right to change this strategy and conduct the business of the Company as appropriate having regard to changes in market or operating conditions. For personal use only